Abstract Number: 512 • 2018 ACR/ARHP Annual Meeting
Incidence of First Cardiovascular Event in Spanish Patients with Chronic Inflammatory Rheumatic Diseases: Prospective Data from an Observational Multicentric Study
Background/Purpose: To determine the incidence and risk factors implicated in the development of first cardiovascular event (CVE) in patients with chronic inflammatory rheumatic diseases (CIRD)…Abstract Number: 645 • 2018 ACR/ARHP Annual Meeting
Real World Secukinumab Study in Ankylosing Spondylitis and Psoriatic Arthritis – Comorbidities and Extraarticular Manifestations: Incidence and Status throughout a Non-Interventional Study in Germany
Background/Purpose: Patients with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) may suffer from extraarticular (EA) manifestations (uveitis, psoriasis) and have higher rates of comorbidities like…Abstract Number: 881 • 2018 ACR/ARHP Annual Meeting
Association of Comorbidities with DAS28 Disease Status and Remission in Race/Ethnic Groups with Rheumatoid Arthritis
Background/Purpose: Racial/ethnic disparities in comorbidity (CM) in rheumatoid arthritis (RA) may confound treatment and outcomes. Rheumatic Disease Comorbidity Index (RDCI) is a validated tool predicting…Abstract Number: 1270 • 2018 ACR/ARHP Annual Meeting
Lack of Association of Comorbidities with Ultrasonographic Urate Deposition in Asymptomatic Hyperuricemia
Background/Purpose: Hyperuricemia is common, and along with other comorbidities (CM), is increasing in prevalence. Though often asymptomatic, it is associated with subclinical urate deposition detectable…Abstract Number: 1514 • 2018 ACR/ARHP Annual Meeting
Impact of Comorbidity Burden and Obesity on the Effectiveness of Tocilizumab in Patients with Rheumatoid Arthritis
Background/Purpose: Few real-world studies have evaluated the impact of comorbidity burden or obesity on the effectiveness of tocilizumab (TCZ) for the improvement of rheumatoid arthritis…Abstract Number: 528 • 2017 ACR/ARHP Annual Meeting
Impact of Comorbidities on the Occurrence of Infections in Rheumatoid Arthritis Treated By Biologic Agents
Background/Purpose: to investigate the potential relationship between the number of comorbidities at initiation of biotherapy and the occurrence of a severe infection or recurrent infections…Abstract Number: 1004 • 2017 ACR/ARHP Annual Meeting
Arthritis Impact at the State and County Level — United States, 2015
Background/Purpose: Arthritis, a leading cause of disability, affects 54.4 million US adults. By knowing the state and county level arthritis impact, state-level public health professionals…Abstract Number: 1036 • 2017 ACR/ARHP Annual Meeting
Blood Glucose Changes Surrounding Initiation of Tumor-Necrosis Factor Inhibitors and Conventional Disease-Modifying Anti-Rheumatic Drugs in Veterans with Rheumatoid Arthritis
Background/Purpose: There is evidence linking activation of the innate immune system and insulin resistance. Perturbations in glucose homeostasis upon initiation of tumor-necrosis factor inhibitors (TNFis)…Abstract Number: 1527 • 2017 ACR/ARHP Annual Meeting
Do TNF Inhibitors Alter the Natural History of Ankylosing Spondylitis By Impacting the Incidence and Prevalence of Comorbidities and Extra-Articular Manifestations?
Background/Purpose: Treatment with TNF inhibitors (TNFi) has led to a reduction in signs and symptoms, and improvement in physical function and quality of life in…Abstract Number: 1902 • 2017 ACR/ARHP Annual Meeting
A Pattern of Higher Serum Levels of IL-10 and MMP-3, Along with Lower IL-6R, Identify RA Patients with Interstitial Lung Disease
Background/Purpose: The pathogenesis and prediction of RA-associated interstitial lung disease (ILD), an extra-articular manifestation with high morbidity and mortality, is poorly understood. We explored the…Abstract Number: 2309 • 2017 ACR/ARHP Annual Meeting
Risk Factors for Arthritis and the Development of Comorbid Cardiovascular and Metabolic Disease in Children with Psoriasis
Background/Purpose: Relatively little is known about the epidemiology of juvenile psoriatic arthritis (PsA), including risk factors for development of PsA among children with psoriasis. It…Abstract Number: 2388 • 2017 ACR/ARHP Annual Meeting
Women and Men with Rheumatoid Arthritis Present with Different Risks for Glucocorticoid-Related Comorbidities
Background/Purpose: Osteoporosis, diabetes, hypertension and cardiovascular diseases are the most threatening glucocorticoid (GC)-related comorbidities in rheumatoid arthritis (RA), both from the patients and rheumatologists perspective1.…Abstract Number: 111 • 2016 ACR/ARHP Annual Meeting
Influences of Osteoarthritis Pain, Comorbid Insomnia, and Depression on Health Care Use in Older Adults with Osteoarthritis
Background/Purpose: Osteoarthritis (OA), the most common type of arthritis, is prevalent and costly. Pain is the principal reason patients with OA seek treatment. Older adults…Abstract Number: 899 • 2016 ACR/ARHP Annual Meeting
Disparities in Disease Characteristics, Treatment Pattern and Comorbidities in 1,858 Patients with Polymyalgia Rheumatica, Giant Cell Arteritis or Both Diseases
Background/Purpose: Methods: Conclusion:Abstract Number: 909 • 2016 ACR/ARHP Annual Meeting
A “Yellow Card” Reporting System for Sight Loss in Giant Cell Arteritis
Background/Purpose: It is reported that 15-25% patients with GCA present with visual complications. Sight loss (SL) in the elderly is associated with considerable morbidity. There…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- 16
- Next Page »